Nan Zhang

4.1k total citations · 2 hit papers
170 papers, 2.4k citations indexed

About

Nan Zhang is a scholar working on Oncology, Surgery and Epidemiology. According to data from OpenAlex, Nan Zhang has authored 170 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Oncology, 54 papers in Surgery and 50 papers in Epidemiology. Recurrent topics in Nan Zhang's work include Cholangiocarcinoma and Gallbladder Cancer Studies (18 papers), Pancreatic and Hepatic Oncology Research (17 papers) and Cancer, Hypoxia, and Metabolism (15 papers). Nan Zhang is often cited by papers focused on Cholangiocarcinoma and Gallbladder Cancer Studies (18 papers), Pancreatic and Hepatic Oncology Research (17 papers) and Cancer, Hypoxia, and Metabolism (15 papers). Nan Zhang collaborates with scholars based in China, United States and Ethiopia. Nan Zhang's co-authors include Mary Walker, Xianqiang Liu, Huan Shi, Haitao Zhao, Yixuan Zhang, Desheng Xiao, Shuang Liu, Lili Li, Yongguang Tao and Wei Zhuang and has published in prestigious journals such as Cell, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Nan Zhang

158 papers receiving 2.4k citations

Hit Papers

Signaling pathways in cancer metabolism: mechanisms and t... 2023 2026 2024 2025 2023 2024 40 80 120
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Signaling pathways in cancer metabolism: mechanisms and therapeutic targets
    2023 146 citations Nan Zhang et al. profile →
  2. Biomarkers and prognostic factors of PD-1/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma
    2024 43 citations Nan Zhang, Yunchao Wang et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nan Zhang China 27 739 728 587 438 402 170 2.4k
Feng Li China 27 707 1.0× 583 0.8× 379 0.6× 466 1.1× 291 0.7× 152 2.5k
Kazuhiro Nomoto Japan 25 527 0.7× 768 1.1× 336 0.6× 380 0.9× 341 0.8× 91 2.2k
Xu Yang China 31 555 0.8× 1.2k 1.6× 367 0.6× 363 0.8× 395 1.0× 151 3.0k
Bing Wan China 27 595 0.8× 961 1.3× 394 0.7× 361 0.8× 878 2.2× 102 2.9k
Yiming Zhao China 31 660 0.9× 1.4k 1.9× 389 0.7× 306 0.7× 545 1.4× 102 2.9k
Nikolaos Kavantzas Greece 30 605 0.8× 1.0k 1.4× 290 0.5× 379 0.9× 243 0.6× 183 2.9k
Chunmei Bai China 28 1.3k 1.8× 996 1.4× 439 0.7× 427 1.0× 299 0.7× 173 2.7k
Wei Yao China 31 648 0.9× 1.2k 1.6× 304 0.5× 322 0.7× 540 1.3× 121 2.6k
Bin Sun China 31 707 1.0× 1.1k 1.5× 297 0.5× 299 0.7× 293 0.7× 94 3.0k

Countries citing papers authored by Nan Zhang

Since Specialization
Citations

This map shows the geographic impact of Nan Zhang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nan Zhang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nan Zhang more than expected).

Fields of papers citing papers by Nan Zhang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nan Zhang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nan Zhang. The network helps show where Nan Zhang may publish in the future.

Co-authorship network of co-authors of Nan Zhang

This figure shows the co-authorship network connecting the top 25 collaborators of Nan Zhang. A scholar is included among the top collaborators of Nan Zhang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nan Zhang. Nan Zhang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhou, Zhen, Yifeng Gao, Weiwei Zhang, et al.. (2025). Deep Learning and Radiomics Discrimination of Coronary Chronic Total Occlusion and Subtotal Occlusion using CTA. Academic Radiology. 32(7). 3892–3902.
2.
Pan, Ruijun, Yiqing Shen, Xue Wang, et al.. (2025). Development and validation of a postoperative prognostic model for hormone receptor positive early stage breast cancer recurrence. Scientific Reports. 15(1). 9905–9905.
3.
4.
5.
Wang, Xinguang, Qijun Zheng, Yingjian He, et al.. (2024). Diagnostic accuracy of sentinel lymph node biopsy and wire localized clipped node biopsy after neoadjuvant chemotherapy in node-positive breast cancer. Surgery Today. 55(2). 172–179. 1 indexed citations
6.
Zhu, Chengpei, Shanshan Wang, Yunchao Wang, et al.. (2024). Efficacy and safety of lenvatinib combined with anti-PD-1 antibodies plus GEMOX chemotherapy as non-first-line systemic therapy in advanced gallbladder cancer. Cancer Immunology Immunotherapy. 73(12). 240–240. 1 indexed citations
7.
Ye, Jing, et al.. (2024). Deubiquitinases as novel therapeutic targets for diseases. SHILAP Revista de lepidopterología. 5(12). e70036–e70036. 11 indexed citations
8.
Deng, Yanan, Ying Chen, Shan Gao, et al.. (2024). RREB1-mediated SUMOylation enhancement promotes chemoresistance partially by transcriptionally upregulating UBC9 in colorectal cancer. Frontiers in Pharmacology. 15. 1381860–1381860. 4 indexed citations
9.
Zhang, Nan, et al.. (2024). Optimizing the Return Vent Height for Improved Performance in Stratified Air Distribution Systems. Buildings. 14(4). 1008–1008. 1 indexed citations
10.
Wang, Yunchao, Xiaobo Yang, Yanyu Wang, et al.. (2023). Effectiveness and safety of radiotherapy plus programmed death-1 inhibitors and lenvatinib in patients with advanced biliary tract carcinoma: a real-world study. Cancer Immunology Immunotherapy. 72(7). 2197–2204. 5 indexed citations
11.
Ma, Jinxia, Lipei Shao, Hui Liu, et al.. (2023). Reference gene selection for clinical chimeric antigen receptor T-cell product vector copy number assays. Cytotherapy. 25(6). 598–604. 8 indexed citations
12.
Chao, Jiashuo, Shanshan Wang, Hao Wang, et al.. (2023). Real-world cohort study of PD-1 blockade plus lenvatinib for advanced intrahepatic cholangiocarcinoma: effectiveness, safety, and biomarker analysis. Cancer Immunology Immunotherapy. 72(11). 3717–3726. 14 indexed citations
13.
Wang, Yunchao, Nan Zhang, Jingnan Xue, et al.. (2023). Safety and feasibility of toripalimab plus lenvatinib with or without radiotherapy in advanced BTC. Frontiers in Immunology. 14. 1084843–1084843. 8 indexed citations
14.
Wang, Zihan, Jinping Wang, Liubo Zhang, et al.. (2023). Role and mechanism of fibroblast-activated protein-α expression on the surface of fibroblast-like synoviocytes in rheumatoid arthritis. Frontiers in Immunology. 14. 1135384–1135384. 19 indexed citations
15.
Chen, Jingshu, Nan Zhang, Benqiang Yang, et al.. (2023). New insight in massive cerebral infarction predictions after anterior circulation occlusion. Scientific Reports. 13(1). 23021–23021. 9 indexed citations
16.
17.
Yang, Hong, Zhendan Yao, Ming Cui, et al.. (2020). Influence of tumor location on short- and long-term outcomes after laparoscopic surgery for rectal cancer: a propensity score matched cohort study. BMC Cancer. 20(1). 761–761. 6 indexed citations
18.
Liu, Fengping, Nan Zhang, Jiang Peng, et al.. (2020). Characteristics of the urinary microbiome in kidney stone patients with hypertension. Journal of Translational Medicine. 18(1). 130–130. 36 indexed citations
19.
Liu, Dequan, Yun Yu, Xinyu Hu, et al.. (2019). What Is the Biological Function of Uric Acid? An Antioxidant for Neural Protection or a Biomarker for Cell Death. Disease Markers. 2019. 1–9. 38 indexed citations
20.
Casares, Sofía, Marvin Lin, Nan Zhang, et al.. (2008). A Peptide-Major Histocompatibility Complex II Chimera Favors Survival of Pancreatic β-Ιslets Grafted in Type 1 Diabetic Mice. Transplantation. 85(12). 1717–1725. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Feng Li Breakdown of academic impact, for papers by Kazuhiro Nomoto Breakdown of academic impact, for papers by Xu Yang Breakdown of academic impact, for papers by Bing Wan Breakdown of academic impact, for papers by Yiming Zhao Breakdown of academic impact, for papers by Nikolaos Kavantzas Breakdown of academic impact, for papers by Chunmei Bai Breakdown of academic impact, for papers by Wei Yao Breakdown of academic impact, for papers by Bin Sun
Rankless by CCL
2026